"The clinical trial for panobinostat is now in the advanced stages of trial development, and we anticipate opening to enrollment in a matter of months. The trial will be conducted across the US within the 10 sites of the Pediatric Brain Tumor Consortium (http://www.pbtc.org), including Stanford. It will be open to children experiencing progression or recurrence of disease."
CANCER NEWSPAPER: Immune system is where we need to expose and further understand how our chromosones mutate for the Cancer to form. Join with me on the Journey to expose Cancer....Without action we go no where. www.cannabissoulhealing.com
Showing posts with label brain Cancer. Show all posts
Showing posts with label brain Cancer. Show all posts
Saturday, 23 May 2015
Monday, 4 May 2015
DIPG- Study points to possible treatment
Using brain tumor samples collected from children in the United States and Europe, an international team of scientists found that the drug panobinostat and similar gene regulating drugs may be effective at treating diffuse intrinsic pontine gliomas (DIPG), an aggressive and lethal form of pediatric cancer. The study, published in Nature Medicine, was partially funded by the National Institutes of Health, the Department of Defense, and more than 25 nonprofit foundations devoted to finding cures for childhood brain cancer.
“Our results provide a glimmer of hope for treating this heartbreaking disease,” said Michelle Monje, M.D., Ph.D., assistant professor of neurology and neurological sciences, Stanford University School of Medicine, California, a senior author of the study and a specialist in DIPG. “Caring for DIPG patients drives me to find new ways to treat them.”
“Our results provide a glimmer of hope for treating this heartbreaking disease,” said Michelle Monje, M.D., Ph.D., assistant professor of neurology and neurological sciences, Stanford University School of Medicine, California, a senior author of the study and a specialist in DIPG. “Caring for DIPG patients drives me to find new ways to treat them.”
Saturday, 21 February 2015
Cancer research breaking through Brain Cancer
Aljen Projects has put within the Cannabis Soul Healing are working on another arm of this same research.
SAN ANTONIO - The Texas Cancer Prevention and Research Institute grants $6.6 million dollars to researchers from the UT Health Science Center, specifically the Cancer Therapy and Research Center (CTRC). $2 million of that will go to produce a potentially life-saving treatment. CTRC already has FDA approval to start drug development and treating San Antonio patients.
Patients diagnosed with Glioblastoma have limited hope.
"Currently surgery and radiation are really the only major therapies," says Steve Weitman, MD, PhD, Director of the Institute for Drug Development for the CTRC.
"It is a fatal disease and that's where again I think from our side we wanted to focus in on that particular tough cancer," says Weitman.
Glioblastoma is the most aggressive form of brain cancer, but local researchers are working with what they hope is the cure.
The Cancer Therapy and Researh Center at the UT Health Science Center has been given a grant and the okay from the FDA for drug development and to treat patients after successful results in preclinical trials.
"In most cases, if the animals are not treated, they succumb to the tumor within a period of days to weeks, with this new therapy, they actually survive. This really is a technology that essentially implants a small amount of radioactivity into a fat gobule."
And in these images, you can see the comparison. These show an untreated tumor. Within 2 weeks, it has almost tripled in size.
These images show a similar sized tumor essentially gone 70 days post treatment.
"The radioactivity is slowly released and essentially cleans up and removes any cancer cells that may be in the brain," says Weitman.
NanoTx Therapeutics is the company formed to commercialize this nanotherapy drug. Patients will start receiving treating within the next few weeks.
Andrew Brenner, M.D., Ph.D., a neuro-oncologist at CTRC will lead this clinincal trial. In addition to the product development, the remainder of the $6.6 million grant will got to the following CTRC research:
-Insight into Ewing’s Sarcoma: Alexander Bishop, D.Phil., associate professor of cellular and structural biology, $2 million, 4-year grant
-Developing a one-two-three punch drug for lymphoma: Ricardo Aguiar, M.D., Ph.D., associate professor of medicine and biochemistry in the School of Medicine at the Health Science Center, $900,000, 3-year grant
-Learning how to stop the painful side effects of chemotherapy: James D. Stockand, Ph.D., professor of physiology, $844,000, 3-year grant
-The benefits of resveratrol in keeping prostate cancer at bay: A. Pratap Kumar, Ph.D., professor of http://news4sanantonio.com/m/news/features/top-stories/stories/A-major-medical-breakthrough-right-here-in-San-Antonio-87315.shtml#.VOj11nyUdgOurology, $900,000, 3-year grant
Subscribe to:
Posts (Atom)